Metastatic spread of cancers from their primary site to secondary sites around the body is not a new phenomenon, but still poses major challenges for cancer care teams. In cases of colorectal cancer, the most common site that the cancer metastasizes to is the liver, but thanks to improvements in how these cancers are treated has meant that 40-60% or patients treated for colon cancer liver metastases are able to survive for five or more years. Considerations to be made in cases of colorectal cancer metastasizing to the liver are made by the whole of the cancer care team and must take many factors into consideration, from the treatment methods to implement with the aim of treating the cancer or preventing progression of disease (i.e. surgery, chemotherapy, radiotherapy, immunotherapy), to the considerations outside of treatment which aim to improve quality of life and patient outcomes.
Considerations in cancers spreading from the colon to the liver must be handled as you would any other cancer diagnosis, but with certain case specific considerations. A bottom up approach should be implemented, beginning with a thorough diagnosis of the cancer, and thorough consideration of the initial therapeutic interventions to be trialed. Both organs, colon and liver, have very specific functions within the body, and preserving this is of vital importance as not doing so can have major implications on a person’s quality of life. Consideration should be made throughout the duration of treating a person for cancer, and assessments on the efficacy of treatments already implemented should be critiqued before reassessing and implementing alternatives.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- Shortcoming in current treatment pathways for colorectal cancers metastasizing to the liver
- Refinements to current diagnostic methods
- Novel treatment methods to improve outcomes
- Ways to improve the quality of life for patients of colorectal cancer that have metastasized to the liver
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Metastatic spread of cancers from their primary site to secondary sites around the body is not a new phenomenon, but still poses major challenges for cancer care teams. In cases of colorectal cancer, the most common site that the cancer metastasizes to is the liver, but thanks to improvements in how these cancers are treated has meant that 40-60% or patients treated for colon cancer liver metastases are able to survive for five or more years. Considerations to be made in cases of colorectal cancer metastasizing to the liver are made by the whole of the cancer care team and must take many factors into consideration, from the treatment methods to implement with the aim of treating the cancer or preventing progression of disease (i.e. surgery, chemotherapy, radiotherapy, immunotherapy), to the considerations outside of treatment which aim to improve quality of life and patient outcomes.
Considerations in cancers spreading from the colon to the liver must be handled as you would any other cancer diagnosis, but with certain case specific considerations. A bottom up approach should be implemented, beginning with a thorough diagnosis of the cancer, and thorough consideration of the initial therapeutic interventions to be trialed. Both organs, colon and liver, have very specific functions within the body, and preserving this is of vital importance as not doing so can have major implications on a person’s quality of life. Consideration should be made throughout the duration of treating a person for cancer, and assessments on the efficacy of treatments already implemented should be critiqued before reassessing and implementing alternatives.
We welcome Original Research, leading-edge Reviews and Clinical Trials related but not limited to the aspects below:
- Shortcoming in current treatment pathways for colorectal cancers metastasizing to the liver
- Refinements to current diagnostic methods
- Novel treatment methods to improve outcomes
- Ways to improve the quality of life for patients of colorectal cancer that have metastasized to the liver
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
